What Needs to Be True Across Sponsors, Sites, and Regulators for Operation TrialBlazer to SucceedByAmber Hill, PhD,Andy Studna, Senior EditorAugust 21st 2026
ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP TreatmentByAndy Studna, Senior EditorAugust 21st 2026
Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial OperationsByAndy Studna, Senior EditorAugust 20th 2026
Where AI Has the Most Immediate Impact in Phase I ExecutionByAmber Hill, PhD,Andy Studna, Senior EditorAugust 20th 2026
ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA CommissionerByAndy Studna, Senior EditorAugust 20th 2026